Imfinzi

Give as IV infusion over 60mins. BTC: (<30kg): 20mg/kg (with chemotherapy) every 3 weeks up to 8 cycles, followed by 20mg/kg every 4 weeks as a single agent; (≥30kg): 1500mg (with chemotherapy) every 3 weeks up to 8 cycles, followed by 1500mg every 4 weeks as a single agent; continue until disease progression or unacceptable toxicity. uHCC: (<30kg): 20mg/kg (with tremelimumab-actl 4mg/kg as a single dose) at Day 1 of Cycle 1, followed by 20mg/kg every 4 weeks as a single agent; (≥30kg): 1500mg (with tremelimumab-actl 300mg as a single dose) at Day 1 of Cycle 1, followed by 1500mg every 4 weeks as a single agent; after Cycle 1 of combination therapy, continue until disease progression or unacceptable toxicity. In combination with chemotherapy: give durvalumab prior to chemotherapy on the same day (see full labeling). In combination with tremelimumab-actl: give tremelimumab-actl prior to durvalumab on the same day (see full labeling). Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.

Give as IV infusion over 60mins. Unresectable, Stage III NSCLC (<30kg): 10mg/kg every 2 weeks; (≥30kg): 10mg/kg every 2 weeks or 1500mg every 4 weeks; continue until disease progression, unacceptable toxicity, or max 12 months. Metastatic NSCLC: non-squamous or squamous: (<30kg): 20mg/kg every 3 weeks (with tremelimumab-actl 1mg/kg and platinum-based chemotherapy) for 4 cycles, followed by 20mg/kg every 4 weeks as a single agent (with histology-based pemetrexed therapy) every 4 weeks, and a fifth dose of tremelimumab-actl 1mg/kg (with durvalumab dose 6) at week 16;  (≥30kg): 1500mg every 3 weeks (with tremelimumab-actl 75mg and platinum-based chemotherapy) for 4 cycles, followed by 1500mg every 4 weeks as a single agent (with histology-based pemetrexed maintenance therapy) every 4 weeks, and a fifth dose of tremelimumab-actl 75mg (with durvalumab dose 6) at week 16. Continue durvalumab until disease progression or intolerable toxicity. In combination with tremelimumab-actl and chemotherapy: give tremelimumab-actl first, followed by durvalumab and then platinum-based chemotherapy on the day of dosing (see full labeling). If patients receive fewer than 4 cycles of chemotherapy, give remaining tremelimumab-actl cycles (up to a total of 5) after chemotherapy phase, in combination with durvalumab, every 4 weeks. For patients with non-squamous disease who received pemetrexed and carboplatin/cisplatin: optional pemetrexed therapy from week 12 until disease progression or intolerable toxicity. ES-SCLC (<30kg): 20mg/kg (with chemotherapy) every 3 weeks for 4 cycles, followed by 10mg/kg every 2 weeks as a single agent; (≥30kg): 1500mg (with chemotherapy) every 3 weeks for 4 cycles, followed by 1500mg every 4 weeks as a single agent. Continue until disease progression or unacceptable toxicity. In combination with chemotherapy: give durvalumab prior to chemotherapy on the same day (see full labeling). Dose modifications: see full labeling. Administer corticosteroids for most Grade ≥2 related immune-mediated reactions.